As the U.S. moves towards a value-based healthcare system, the data inputs and evidence base used to drive this shift must reflect the diversity of patients and represent the different values that patients hold for their health and healthcare. Historically, many patient communities are underrepresented in research and have been left out of the development of measures and methods for value assessment.

IVI is engaging advisors and stakeholders to explore formative questions:

  • How do we ensure that the data and methods used for value assessment adequately account for the diversity of patients?
  • How can value assessment meet the urgent need to reduce health inequities in our society?

Without explicit attention to these issues, value assessments and health technology assessments run the risk of continuing or exacerbating inequity.

Through this initiative, IVI seeks to embed health equity throughout our research projects, educational offerings, and patient and stakeholder engagement activities to catalyze action in the development of methods in value assessment that promote equity in health access and outcomes.

Initiative Objectives

Timeline

Steering Committee

By launching the Health Equity Initiative, IVI aims to advance multi-stakeholder dialogue about best practices and opportunities for meaningful change in the valuation of health care to recognize diversity, address existing health disparities, and promote equitable access to care. To achieve the goals of the initiative, IVI scientific leadership is leading a series of activities, guided by a collaborative, expert steering group and with facilitated input from a select group of invited methods and research experts.

View Steering Committee

Initiative Sponsors

IVI is seeking sponsors to help underwrite the IVI Health Equity Initiative. If you are interested in becoming a sponsor, please contact Melanie Ridley (melanie.ridley@thevalueinitiative.org), Director of Fund Development and Partnerships.

The Health Equity Initiative is partially funded through generous support from PhRMA.